Rudenko, Larisa <br/><br/>
Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).  [electronic resource] 

 -  Influenza and other respiratory viruses  Nov 2008 
 - 203-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1750-2659 
<br/><br/><label>Standard No.: </label>10.1111/j.1750-2659.2008.00064.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intranasal<br/>Antibodies, Viral--blood<br/>Cross Reactions<br/>Hemagglutination Inhibition Tests<br/>Humans<br/>Immunization, Secondary<br/>Immunoglobulin A--analysis<br/>Influenza A Virus, H2N2 Subtype--genetics<br/>Influenza A Virus, H5N1 Subtype--immunology<br/>Influenza A Virus, H5N2 Subtype--genetics<br/>Influenza Vaccines--administration & dosage<br/>Influenza, Human--prevention & control<br/>Nasal Mucosa--immunology<br/>Neutralization Tests<br/>Reassortant Viruses--genetics<br/>Russia<br/>Vaccines, Attenuated--administration & dosage